Skip to search form
Skip to main content
Semantic Scholar's Logo
Create Free Account
You are currently offline. Some features of the site may not work correctly.
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion
Cancer Chemotherapy and Pharmacology
Corpus ID: 42646733
Summary502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor…
In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol
W. T. van der Graaf
J. G. Zijlstra
E. de Vries
Corpus ID: 2799531
BW502U83, an arylmethylaminopropanediol (AMAP), showed to be partially cross-resistant in a P-glycoprotein-positive and in a P…
Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83.
C. W. Sigel
Drug metabolism and disposition: the biological…
Corpus ID: 26635526
The pharmacokinetics, metabolism, and qualitative tissue distribution of 502U83, a compound with antineoplastic activity, were…
Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients
Corpus ID: 22391701
502U83, a novel arylmethylaminopropanediol, has proven active In vivo against a panel of murlne leukemia and solid tumors as well…
Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
D. V. Von Hoff
Corpus ID: 7371411
502U83 is an arylmethylaminopropanediol derivative exhibiting significant antineoplastic activity in a number of murine and human…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE